Literature DB >> 18283522

Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period.

Nobuhide Hayashi1, Masahiro Koshiba, Kunihiro Nishimura, Daisuke Sugiyama, Tomoko Nakamura, Sahoko Morinobu, Seiji Kawano, Shunichi Kumagai.   

Abstract

The aim of this study was to investigate the types and prevalence of disease-specific antinuclear antibodies (ANAs) and their relationship to rheumatic diseases in the general Japanese population. An immunofluorescence (IF) method was used for the first screening of ANA levels in serum samples obtained from 2181 residents of a small Japanese town. Individuals positive for IF-ANA were then further tested for disease-specific ANAs using eight enzyme immunoassays. Physical status and the presence of illness were determined by means of questionnaires and medical examinations. Based on the result of the IF-ANA assay, the rates of positive samples at 1:40 and 1:160 dilutions were 26.0 and 9.5%, respectively, with females have significantly higher positivity rates than males (P < 0.0001). Among 566 IF-ANA-positive individuals, 100 individuals were found to have 114 disease-specific ANAs. Anti-SSA/Ro, anti-centromere, and anti-U1RNP antibodies were detected in 58, 30, and 11 individuals, respectively, but anti-Sm, anti-Scl-70, and anti-Jo-1 antibodies were undetectable. Questionnaires and medical examinations revealed that among 60 disease-specific ANA-positive individuals that were available for testing, six had Sjögren's syndrome (SS), five were suspected of having SS, and five had rheumatoid arthritis. Surprisingly, 34 (57%) of the disease-specific ANA-positive individuals were clinically healthy. Anti-SSA/Ro, anti-centromere, and anti-U1RNP antibodies were quite frequent among clinically healthy Japanese subjects, although anti-Sm, anti-Scl-70, and anti-Jo-1 antibodies were not. Of the 60 individuals who tested positive for disease-specific ANAs, 30% (18/60) actually manifested systemic rheumatic diseases, while 50% showed no detectable signs or symptoms of rheumatic diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18283522     DOI: 10.1007/s10165-008-0028-1

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  40 in total

Review 1.  [Choosing wisely recommendations in rheumatology : One year after their first publication].

Authors:  E Märker-Hermann; A J Voormann
Journal:  Internist (Berl)       Date:  2017-06       Impact factor: 0.743

2.  Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study.

Authors:  Minoru Satoh; Malgorzata E Krzyszczak; Yi Li; Angela Ceribelli; Steven J Ross; Edward K L Chan; Mark S Segal; Michael R Bubb; Eric S Sobel; Westley H Reeves
Journal:  Arthritis Res Ther       Date:  2011-05-10       Impact factor: 5.156

3.  Determination of anti-nuclear antibody seroprevalence in adult age groups in trabzon province.

Authors:  Neşe Kaklıkkaya; Altan Akıneden; Murat Topbaş; Faruk Aydın
Journal:  Balkan Med J       Date:  2013-09       Impact factor: 2.021

4.  Prevalence of antinuclear antibodies in healthy Lebanese subjects, 2008-2015: a cross-sectional study involving 10,814 subjects.

Authors:  Eddie Racoubian; Reem M Zubaid; Marwa A Shareef; Wassim Y Almawi
Journal:  Rheumatol Int       Date:  2016-07-13       Impact factor: 2.631

5.  Prevalence of pre-clinical autoimmunity in the normal adult population residing in a metropolitan city of India: A cross-sectional study.

Authors:  Uma Kumar; Maumita Kanjilal; Lakshmy Ramakrishnan; Maheswari Thangavelu
Journal:  Eur J Rheumatol       Date:  2020-09-08

Review 6.  Recent Approaches To Optimize Laboratory Assessment of Antinuclear Antibodies.

Authors:  Anne E Tebo
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

7.  Obstetric and perinatal outcome in anti-Ro/SSA-positive pregnant women: a prospective cohort study.

Authors:  Nuria Martínez-Sánchez; Sergio Pérez-Pinto; Ángel Robles-Marhuenda; Francisco Arnalich-Fernández; María Martín Cameán; Edurne Hueso Zalvide; Jose Luis Bartha
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

8.  Prevalence of Myositis-Specific Antibodies in Idiopathic Interstitial Pneumonias.

Authors:  Laurens J De Sadeleer; Ellen De Langhe; Nicolas Bodart; Alain Vigneron; Xavier Bossuyt; Wim A Wuyts
Journal:  Lung       Date:  2018-03-12       Impact factor: 2.584

Review 9.  Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

Authors:  Minoru Satoh; Monica Vázquez-Del Mercado; Edward K L Chan
Journal:  Mod Rheumatol       Date:  2009-03-10       Impact factor: 3.023

10.  Clinical significance of serum autoantibodies in idiopathic interstitial pneumonia.

Authors:  Bo Hyoung Kang; Jin Kyeong Park; Jae Hyung Roh; Jin Woo Song; Chang Keun Lee; Miyoung Kim; Se Jin Jang; Thomas V Colby; Dong Soon Kim
Journal:  J Korean Med Sci       Date:  2013-05-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.